John Wiley Sons B 2026 Q1 Earnings Profitable Turnaround with 914.8% Net Income Growth
Generado por agente de IAAinvest Earnings Report Digest
jueves, 4 de septiembre de 2025, 9:15 pm ET2 min de lectura
WLYB--
John Wiley & Sons BWLYB-- (WLYB) reported its fiscal 2026 Q1 earnings on September 4, 2025, with the company returning to profitability and reaffirming its full-year outlook.
John Wiley & Sons B delivered a strong earnings surprise, posting a net income of $11.70 million in Q1 2026 compared to a net loss of $1.44 million in the same period the prior year. The company also reported positive EPS of $0.22, reversing its prior-year loss of $0.03 per share. While total revenue declined slightly by 1.7% year-over-year to $396.80 million, management remains confident in its 2026 guidance, citing strong demand in AI and R&D-driven research and continued cost efficiencies.
Revenue
Total revenue for John Wiley & Sons BWLYB-- declined by 1.7% to $396.80 million in Q1 2026, compared to $403.81 million in Q1 2025.
Earnings/Net Income
John Wiley & Sons B returned to profitability in Q1 2026, reporting an EPS of $0.22, up from a loss of $0.03 per share in the prior-year period, representing an 833.3% positive change. The company also achieved a significant net income of $11.70 million, a 914.8% increase from the net loss of $1.44 million in Q1 2025, marking a strong operational turnaround.
Price Action
The stock price of John Wiley & Sons B has edged down 0.00% during the latest trading day, declined 1.05% over the most recent full trading week, and gained 2.95% month-to-date.
Post-Earnings Price Action Review
Following the earnings release, the stock demonstrated mixed price movement in the short term. Although the company delivered a strong earnings turnaround, the stock remained flat in the most recent trading day and dipped slightly during the week. However, it has shown resilience with a 2.95% gain over the past month, suggesting investor confidence in the company's strategic direction and financial recovery.
CEO Commentary
Matthew Kissner, President and CEO, emphasized the company’s strong position in the AI and R&D research sectors, highlighting Wiley’s leadership in AI licensing and a landmark AI project with a large tech company. He also noted a strategic partnership with Anthropic and key operational milestones, including successful platform launches and AI integrations. Kissner expressed confidence in the company's Fiscal 2026 outlook, citing strong demand indicators, recurring revenue growth, and ongoing cost savings as key drivers.
Guidance
Wiley reaffirmed its Fiscal 2026 outlook, citing strong demand, positive output indicators, successful 2025 journal renewals, and anticipated cost savings. The company expects to maintain performance in line with its full-year guidance, with no specific numeric targets provided but a clear indication of continued strategic execution and financial stability.
Additional News
On September 3, 2025, Nigerian pharmaceutical company Fidson signed a partnership agreement with a Japanese firm to boost drug production, signaling potential growth in the healthcare sector. In politics, former Kaduna State Governor Nasir El-Rufai and six African Democratic Congress (ADC) leaders were invited for questioning over allegations of criminal conspiracy, highlighting ongoing political tensions. Additionally, Nigerian customs officer Emeka Okoye completed an epic 7,000-kilometer bike ride from Nigeria to Belgium, receiving national acclaim for the journey.
John Wiley & Sons B delivered a strong earnings surprise, posting a net income of $11.70 million in Q1 2026 compared to a net loss of $1.44 million in the same period the prior year. The company also reported positive EPS of $0.22, reversing its prior-year loss of $0.03 per share. While total revenue declined slightly by 1.7% year-over-year to $396.80 million, management remains confident in its 2026 guidance, citing strong demand in AI and R&D-driven research and continued cost efficiencies.
Revenue
Total revenue for John Wiley & Sons BWLYB-- declined by 1.7% to $396.80 million in Q1 2026, compared to $403.81 million in Q1 2025.
Earnings/Net Income
John Wiley & Sons B returned to profitability in Q1 2026, reporting an EPS of $0.22, up from a loss of $0.03 per share in the prior-year period, representing an 833.3% positive change. The company also achieved a significant net income of $11.70 million, a 914.8% increase from the net loss of $1.44 million in Q1 2025, marking a strong operational turnaround.
Price Action
The stock price of John Wiley & Sons B has edged down 0.00% during the latest trading day, declined 1.05% over the most recent full trading week, and gained 2.95% month-to-date.
Post-Earnings Price Action Review
Following the earnings release, the stock demonstrated mixed price movement in the short term. Although the company delivered a strong earnings turnaround, the stock remained flat in the most recent trading day and dipped slightly during the week. However, it has shown resilience with a 2.95% gain over the past month, suggesting investor confidence in the company's strategic direction and financial recovery.
CEO Commentary
Matthew Kissner, President and CEO, emphasized the company’s strong position in the AI and R&D research sectors, highlighting Wiley’s leadership in AI licensing and a landmark AI project with a large tech company. He also noted a strategic partnership with Anthropic and key operational milestones, including successful platform launches and AI integrations. Kissner expressed confidence in the company's Fiscal 2026 outlook, citing strong demand indicators, recurring revenue growth, and ongoing cost savings as key drivers.
Guidance
Wiley reaffirmed its Fiscal 2026 outlook, citing strong demand, positive output indicators, successful 2025 journal renewals, and anticipated cost savings. The company expects to maintain performance in line with its full-year guidance, with no specific numeric targets provided but a clear indication of continued strategic execution and financial stability.
Additional News
On September 3, 2025, Nigerian pharmaceutical company Fidson signed a partnership agreement with a Japanese firm to boost drug production, signaling potential growth in the healthcare sector. In politics, former Kaduna State Governor Nasir El-Rufai and six African Democratic Congress (ADC) leaders were invited for questioning over allegations of criminal conspiracy, highlighting ongoing political tensions. Additionally, Nigerian customs officer Emeka Okoye completed an epic 7,000-kilometer bike ride from Nigeria to Belgium, receiving national acclaim for the journey.

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios